Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1986 April; 79(4): 210–211.
PMCID: PMC1290276

Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.


Fasting serum lipoproteins were measured in 10 untreated patients with carcinoma of the prostate (Group I), 17 patients with non-malignant urological disorders (Group II), and 12 patients on cyproterone acetate (Group III) and 5 on a long-acting luteinizing hormone-releasing hormone (LHRH) analogue (Group IV) for at least 2 months for carcinoma of the prostate. Total high-density lipoprotein (HDL) cholesterol levels were significantly lower in patients in Group III than all the other groups. Very low-density lipoprotein (VLDL) triglyceride levels were significantly higher in patients in Group III than those in Groups II and IV. These results suggest a potentially adverse effect of cyproterone acetate, but not of the long-acting LHRH analogue, on serum lipids, which is likely to be of relevance only in younger patients.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (245K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Walsh PC. Physiologic basis for hormonal theapy in carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):125–140. [PubMed]
  • Shahmanesh M, Bolton CH, Feneley RC, Hartog M. Metabolic effects of oestrogen treatment in patients with carcinoma of prostate: a comparison of stilboestrol and conjugated equine oestrogens. Br Med J. 1973 Jun 2;2(5865):512–514. [PMC free article] [PubMed]
  • Wein AJ, Murphy JJ. Experience in the treatment of prostatic carcinoma with cyproterone acetate. J Urol. 1973 Jan;109(1):68–70. [PubMed]
  • Waxman JH, Wass JA, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Oliver RT. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) 1983 Apr 23;286(6374):1309–1312. [PMC free article] [PubMed]
  • Bradley DD, Wingerd J, Petitti DB, Krauss RM, Ramcharan S. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med. 1978 Jul 6;299(1):17–20. [PubMed]
  • Wallentin L, Varenhorst E. Plasma lipoproteins during treatment with cyproterone acetate in men with prostatic carcinoma. J Clin Endocrinol Metab. 1980 Nov;51(5):1118–1122. [PubMed]
  • Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. [PubMed]
  • Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977 May;62(5):707–714. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press